Bob, this was from quad-list:
>>>
Resent-Date: Tue, 28 Oct 1997 20:41:09 -0800
From: Cstein236(AT)aol.com
Date: Tue, 28 Oct 1997 23:40:30 -0500 (EST)
To: quad-list(AT)eskimo.com
Subject: Re: More what if?
Resent-From: quad-list(AT)eskimo.com
Reply-To: quad-list(AT)eskimo.com
X-Mailing-List: <quad-list(AT)eskimo.com> archive/latest/1645
X-Loop: quad-list(AT)eskimo.com
Resent-Sender: quad-list-request(AT)eskimo.com
Chris Casa Colima in Pomona,Ca is charging 6,000. to the people who are
going to be in the trials. This is not a blind study everyone gets the real
thing.They are looking for 200 people and it starts Feb.1998.If the trials
are sucessful it will be for the public, but med-cal and medcare won't pay
for it. Russ
I am writing on behalf of Acorda Therapeutics, Inc. in response to many
inquiries we have received regarding an advertisement that appeared in this
month's New Mobility. The ad is for "clinical trials" of 4-AP being run by
Jack Segal and the 'Casa Colina Centers for Rehabilitation' in Pomona,
California. The ad states, among other things, that these trials are being
supported by "participant fees." It also states that participants may reside
"in any part of the United States" and be "monitored by their primary
physician".
We believe it is important to inform the SCI community that this
advertisement, and the "clinical trials" to which it refers, are in no way
associated with Acorda or with Acorda's clinical trials of 4-AP.
Acorda's trials are being supported exclusively by Acorda; there are no
"participant fees." In addition, Acorda's trials are using Elan
Corporation's patented formulation of 4-AP: this is a sustained-release oral
formulation that requires only twice a day dosing and gives highly
controllable blood levels, as compared to other available formulations.
Participants in the Acorda-sponsored trials are being recruited and
monitored by leading academic SCI clinical rehabilitation centers, working
together to ensure that the trials are done as expertly as possible, and in
conformance with all FDA regulations.
We hope this information is helpful in avoiding unwarranted concern or
confusion which may arise as a result of the above-mentioned advertisement.
We would be pleased to answer any additional questions. Please address them
to <<acordainc(AT)aol.com>>. Thanks.
Ron Cohen, M.D.
Ron Cohen, M.D.
Acorda Therapeutics, Inc.
145 West 58th Street, Suite #8J
New York, NY 10019
Tel: (212) 376-7553
Fax: (212) 765-8637
E-Mail: acordainc(AT)aol.com
Russ, I talk to Acorda pharmaceuticals, correction: therapeutic's. When I
spoke to them, they knew nothing about any trials people were being charged
for. Nor did they tell me about any trial that was not a double blind test.
Do you remember who you talked to and what their phone number is?
Thank you, Chris
<<<
----
Jim Lubin jlubin(AT)eskimo.com
Bothell, WA, USA <http://www.eskimo.com/~jlubin>
disAbility Resources: <http://www.eskimo.com/~jlubin/disabled>